Global Health Ltd. Share Price

Supreme Court Scrutiny on Medicine Mark-ups

Hospital stocks remain in the spotlight after the Supreme Court raised sharp concerns over steep mark-ups on medicines sold to patients at private hospitals. A bench flagged a cancer drug supplied to retailers at around ₹2,700 but carrying an MRP of ₹27,000 — nearly a tenfold difference — and questioned why the existing 16% trade margin cap on scheduled drugs has not been extended to non-scheduled medicines that dominate the market. The court also directed the Centre to examine practices compelling patients to buy from in-house or designated hospital pharmacies. The matter is listed for further hearing on October 12. The remarks triggered a sharp sell-off, with the BSE Hospitals Index falling about 5% and chains such as

Healthcare, KIMS and others declining 5-6%. Brokerages have assessed the potential earnings hit. Goldman Sachs estimates a 2-7% EBITDA impact in scenarios with no mitigation, though it notes that modest pricing adjustments or greater use of package billing could cushion the effect. Emkay remains constructive on the sector, assigning Buy ratings to KIMS (target ₹850) and Park Medi World, and Add ratings to Max Healthcare (₹1,150), Global Health/Medanta (₹1,500) and Rainbow Children’s Medicare (₹1,550).

See More

Hospital Stocks CRASH! Supreme Court Questions ON!

HOSPITAL RISK-->“Sarkari Hospital Mein Jaan Ka Risk… Private Hospital Mein Jameen-Jaydaad Ka Risk!” erns over steep mark-ups on medicines sold through private hospitals. Stocks including

, Max Healthcare, Fortis Healthcare, Yatharth Hospital, Medanta and Aster DM came under pressure, with several names falling sharply during the session. --->What Did the Supreme Court Question? The Supreme Court was hearing petitions related to medicine pricing, generic prescriptions and medical-device pricing under the Drugs (Prices Control) Order, 2013. During the hearing, the bench highlighted a striking example: A cancer medicine supplied to retailers for around ₹2,700 was cited as carrying an MRP of around ₹27,000. The Court questioned how such a large gap could exist and also raised concerns about hospitals requiring patients to purchase medicines through their own or designated pharmacies. ---->Why Are Hospital Stocks Falling? The market is worried about one simple issue: Medicine mark-ups can be an important part of hospital economics. If hospitals are eventually required to operate with significantly lower medicine margins, it could potentially affect: • Pharmacy-related revenue • EBITDA margins • Profitability • Revenue per patient ---->The 16% Rule — Don't Misunderstand It This is where the headlines can become misleading. The Supreme Court questioned whether a uniform 16% margin could be applied more broadly. But: The Court has NOT ordered a universal 16% cap on all medicines. The existing 16% retailer-margin concept is already used in parts of India's drug-price-control framework for scheduled formulations. ---->Bottom Line Hospital stocks are falling because the Supreme Court has put hospital medicine mark-ups and captive pharmacy practices under the regulatory spotlight. The market is currently pricing in the risk of tighter regulation, not a confirmed 16% margin cap.

See More

Medanta acquires ₹166 crore land in Ghaziabad

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628 Global Health Limited (

), which operates Medanta hospitals, has acquired land in Ghaziabad for ₹165.82 crore to develop a multispecialty hospital with more than 350 beds. What happened? The company acquired a 10,560.36 sq. metre freehold land parcel in Siddharth Vihar through an online auction conducted by the Uttar Pradesh Housing & Development Board. The proposed hospital remains subject to approval of the detailed project plan and other regulatory clearances. Why does it matter? The acquisition expands Medanta's presence in Delhi-NCR, where it already operates hospitals in Gurugram and Noida. A new hospital could increase its patient reach and strengthen its regional network. However, land acquisition is only one component of the total project investment. My view Hospital expansion requires substantial upfront capital, while revenue builds gradually as patient occupancy increases. The important question is whether Medanta can use its existing brand and regional network to attract patients quickly enough to justify the investment. Construction costs, medical staffing and the time taken to reach optimal occupancy will determine the project's returns. What I am watching next I would track project approval, total investment, construction timelines and the expected commissioning date. Once operational, occupancy and average revenue per occupied bed will be important indicators. No Recommendations Source: Business Standard / Global Health exchange disclosure Disclosure: I, my entity, associates or relatives do not have any holding, position or other material interest in Global Health Limited.

See More

GLOBAL HEALTH LTD – TECHNICAL ANALYSIS With Discussion

Global Health Ltd is currently showing an interesting technical setup on the daily chart. The stock has witnessed a strong upward movement from lower levels and is now consolidating around the ₹1,470 zone. The overall price structure remains positive, but the recent candles indicate some volatility and profit booking near the higher levels. Traders should closely monitor the immediate support and resistance zones for the next directional move. The chart suggests that the ₹1,420–₹1,380 zone may act as an important support area. As long as the stock manages to sustain above this zone, the broader bullish structure may remain intact. On the upside, ₹1,500–₹1,540 appears to be an important resistance zone. A sustained breakout above this level could strengthen bullish momentum and may open the door for further upside. The moving averages and price structure indicate that the stock is currently in a consolidation phase after a strong rally. Volume and price action should be monitored closely for confirmation of the next trend. A breakout with strong volume may attract fresh buying interest, while a breakdown below the key support zone could increase selling pressure. Key Levels to Watch: 📈 Resistance: ₹1,500 | ₹1,540 | ₹1,585 📉 Support: ₹1,420 | ₹1,380 | ₹1,339 ⚠️ Disclaimer: This technical analysis is for educational and informational purposes only and should not be considered as investment advice. Please use proper risk management and consult a qualified financial advisor before making any trading or investment decision.

See More

Global Health Ltd. – Bullish Setup Discussion

The stock is currently consolidating near a key support zone, with fresh buying interest emerging after a strong bullish candle. Price action indicates that the support area around ₹1402–₹1438 is holding well, while short-term bullish momentum is gradually improving. The broader rising channel structure remains intact, keeping the overall technical setup positive as long as the important support levels are defended. 🔎 Technical View: • Strong support holding around ₹1402–₹1438 • Fresh buying interest visible near support • Bullish momentum showing signs of improvement • Rising channel structure remains intact • ₹1473 is the key breakout level to watch • Sustained price action above resistance may strengthen the bullish setup 🔑 Key Levels: 🟢 Support: ₹1438 / ₹1402 🟢 Major Support: ₹1367–₹1345 🔴 Resistance: ₹1473 / ₹1509 🚀 Potential Upside Levels: 🎯 ₹1473 🎯 ₹1509 🎯 ₹1545 🎯 ₹1580+ 📈 Trading View: A sustained move above ₹1473 could trigger fresh bullish momentum and potentially open the way towards ₹1509, ₹1545 and ₹1580+ levels. On the downside, ₹1402 remains an important risk level. A decisive breakdown below ₹1402 could weaken the current setup and increase the possibility of a move towards ₹1367–₹1345. Traders should closely monitor price action, volume and overall market conditions around these key levels, as volatility can impact the movement significantly. ⚠️ For educational purposes only. Not a buy/sell recommendation. Please conduct your own research and consult a SEBI-registered investment professional before making any investment decision. — AALGO BREATHS 📊

See More

Medanta Breaks Major Resistance, Eyes New Highs

Global Health, operating under the Medanta brand, continues to strengthen its fundamental profile through strong patient volumes, capacity expansion and improving contribution from newer hospitals. Q1 FY27 consolidated total income rose 26.2% YoY to ₹1,326 crore, while EBITDA increased 23.5% to ₹315 crore. Patient volumes remained robust, with IP volumes growing 28% and OP volumes rising 34% YoY, highlighting healthy demand across the network. The Noida facility is also moving closer to profitability, reducing the drag from newer capacity. Management is simultaneously pursuing a large expansion pipeline, including the revised Guwahati project that will increase planned capacity to 650 beds. Technically, Medanta has delivered a significant breakout from a multi-year descending resistance structure visible on the daily chart. The stock had been consolidating within a broad contracting formation since the 2024 peak, with resistance gradually declining from the ₹1,550–₹1,600 region while the lower boundary established support near ₹950–₹1,000. The recent rally has taken the price through the upper trendline and the previous resistance around ₹1,400, with the stock now trading close to its lifetime-high zone. This breakout is important because it marks a transition from a prolonged consolidation phase into potential price discovery. Sustained trading above ₹1,400–₹1,420 would keep the breakout intact, while a decisive move above the recent high near ₹1,450 can reinforce the bullish structure and open the possibility of fresh all-time highs. On the downside, ₹1,350–₹1,400 becomes the first important support zone, followed by ₹1,250–₹1,300. As long as the breakout zone holds on closing basis, the technical bias remains firmly bullish.

See More